| Autor: |
Purushothama S; Development Biomarkers & Bioanalytical Sciences, Biogen, Cambridge, MA 02142, USA., Dysinger M; Alexion Pharmaceuticals, New Haven, CT 06510, USA., Chen Y; Pharmaceutical Chemistry, University of Kansas, Lawrence, KS 66045, USA., Österlund K; Gyros Protein Technologies AB, Uppsala 751 83, Sweden., Mora J; Bioanalytical Sciences Biologics, Bristol-Myers Squibb, Princeton, NJ 08540, USA., Chunyk AG; BioMedicine Design, Pfizer, Inc., La Jolla, CA 92037, USA., Peloquin R; SQI Diagnostics, Inc., Toronto, ON M9W 1A4, Canada. |
| Abstrakt: |
This manuscript aims to provide insights and updates on emerging technologies from a throughput and multiplexing perspective and to update readers on changes in previously reported technologies. The technologies discussed range from nascent (ultrasensitive Cira, Intellicyt ® , Dynaxi and Captsure™) to the more established (Ella and SQIDlite™). For the nascent technologies, there was an emphasis on user interviews and reviews, where available, to help provide an unbiased view to our readers. For the Ella, a review of published user data as well as author and other user experiences are summarized. Due to their emergent nature, all the technologies described are applicable in the early drug development stage, may require an upfront investment of capital and may not perform as expected. |
